Opinion

Video

Management of Comment Adverse Effects Associated with mCRPC Therapies

Author(s):

Gautam Jayram, MD,Christopher Pieczonka, MD

Key opinion leaders explore strategies for managing common side effects associated with metastatic castration-resistant prostate cancer (mCRPC) treatments, including androgen receptor-targeted therapies.

Current Time 0:00
Duration 2:28
Loaded: 6.60%
Stream Type LIVE
Remaining Time 2:28
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected

    How do you manage common side effects associated with mCRPC treatments, including androgen receptor-targeted therapies?

    Related Videos
    Michael S. Cookson, MD, FACS, and Kelly L. Stratton, MD, FACS, answer a question during a Zoom video interview
    Special Report: Tips for PCPs on evaluating prostate cancer risk
    Michael S. Cookson, MD, FACS, and Kelly L. Stratton, MD, FACS, answer a question during a Zoom video interview
    Special Report: Tailoring prostate cancer care for older adults
    Michael S. Cookson, MD, FACS, and Kelly L. Stratton, MD, FACS, answer a question during a Zoom video interview
    Special Report: New strategies emerge for metastatic prostate cancer
    Michael S. Cookson, MD, FACS, and Kelly L. Stratton, MD, FACS, answer a question during a Zoom video interview
    Special Report: Biden’s prostate cancer diagnosis renews focus on screening guidelines
    4 experts in this video
    Case 1: A 79-Year-Old Man With Non–Muscle-Invasive Bladder Cancer
    An Overview Of Pembrolizumab for High-Risk BCG Unresponsive NMIBC
    An Overview Of Pembrolizumab for High-Risk BCG Unresponsive NMIBC
    1 expert is featured in this series.
    Case 2: A 63-Year-Old Man With Recurrent HSPC
    1 expert is featured in this series.
    Comorbidities and Adherence: Tailoring mHSPC Treatment
    FDA-Approved Options for High-Risk BCG-Unresponsive NMIBC
    FDA-Approved Options for High-Risk BCG-Unresponsive NMIBC
    De novo metastatic prostate cancer: Understanding Biden’s prognosis and treatment
    De novo metastatic prostate cancer: Understanding Biden’s prognosis and treatment
    Related Content
    FDA Advisory Committee unanimously votes against talazoparib plus enzalutamide for mCRPC
    May 21st 2025

    FDA Advisory Committee unanimously votes against talazoparib plus enzalutamide for mCRPC

    Hannah Clarke
    The application is seeking an expanded indication of talazoparib plus enzalutamide for mCRPC.
    Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD
    May 17th 2025

    Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD

    Amy M. Pearlman, MD Alex Tatem, MD
    Explore the latest insights on testosterone therapy, its benefits, and practical applications from leading urologists in men's health.
    Meeting with FDA paves way for phase 3 trial of PT-112 in mCRPC
    May 20th 2025

    Meeting with FDA paves way for phase 3 trial of PT-112 in mCRPC

    Hannah Clarke
    The phase 3 study design will now be submitted for final review by the agency.
    Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25
    May 4th 2025

    Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25

    Amy M. Pearlman, MD Kevin C. Zorn, MD, FRCSC, FACS
    Urologists discuss innovative BPH treatments, emphasizing personalized care, and the importance of ejaculatory preservation.
    SBRT may offer a safe alternative to CFRT after prostatectomy
    May 16th 2025

    SBRT may offer a safe alternative to CFRT after prostatectomy

    Hannah Clarke
    Data from the SCIMITAR trial showed that SBRT appeared safe and demonstrated comparable PROs compared with CFRT.
    Woman talking with a doctor online using digital tablet | Image Credit: © rh2010 - stock.adobe.com
    May 15th 2025

    Telehealth in urologic cancer: Lessons learned from the COVID-19 pandemic

    Tracey L. Krupski, MD Jeunice Owens-Walton, MD
    "The use of telemedicine is heavily dependent on supportive legislature," write Tracey L. Krupski, MD, and Jeunice Owens-Walton, MD.
    © 2025 MJH Life Sciences

    All rights reserved.